hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06333522 id: 23-00979 briefTitle: Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-01-01 date: 2026-01-01 date: 2024-03-27 date: 2024-03-27 name: NYU Langone Health class: OTHER briefSummary: The purpose of this study is to determine the effect of Losartan, an Angiotensin II Receptor Blocker (ARB), on the formation development of arthrofibrosis in patients who have had a primary total knee arthroplasty. This study aims to assess the post-operative range of motion and the incidence of MUA within three months following the index arthroplasty in the treatment arm (losartan) and the control arm. conditions: Arthrofibrosis of Knee studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 240 type: ESTIMATED name: Losartan measure: Change in range of motion measure: Rate of manipulation under anesthesia (MUA) after elective total knee arthroplasty sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06333509 id: CT071-HM-01 briefTitle: Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-06-15 date: 2027-12-31 date: 2024-03-27 date: 2024-03-27 name: CARsgen Therapeutics Co., Ltd. class: INDUSTRY briefSummary: A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia. conditions: Multiple Myeloma conditions: Primary Plasma Cell Leukemia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Phase 1; Dose escalation followed by dose expansion Phase 2; Single group of each indication will be dosed at the recommended dose level from Phase 1. primaryPurpose: TREATMENT masking: NONE maskingDescription: N/Ap count: 166 type: ESTIMATED name: CT071 measure: Phase 1: Evaluation of the Safety of CT071 and determination of Maximum Tolerated Dose (MTD). measure: Phase 2: Objective response rate measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes measure: Phase 1 and 2: Evaluate additional clinical efficacy outcomes measure: Phase 2: Evaluate additional Safety of CT071. measure: Phase 1 and 2: Assess immunogenicity of CT071 measure: Phase 1 and 2: Evaluate PK profile of CT071 measure: Phase 1 and 2: Evaluate PK profile of CT071 measure: Phase 1 and 2: Evaluate PK profile of CT071 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333496 id: AB20240102H briefTitle: Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-02 date: 2024-03-29 date: 2024-04-08 date: 2024-03-27 date: 2024-04-15 name: Alpine Biotech LLC class: INDUSTRY briefSummary: BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints. conditions: Blood Sugar; High conditions: Overweight and Obesity conditions: Fat Burn conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: GLP1 Booster (GB) measure: blood glucose level measure: blood HbA1c level measure: blood insulin level measure: blood GLP1 level measure: blood cholesterol level measure: body weight measure: body fat mass measure: body lean mass measure: body mass index measure: body fat index measure: waist hip ratio measure: Satiety score measure: Resting metabolic rate measure: Blood pressure measure: Heart rate sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alpine Bio city: Salt Lake City state: Utah zip: 84109 country: United States lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06333483 id: AUTO1-SL1 id: 2023-508236-60-00 type: CTIS briefTitle: A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) acronym: CARLYSE overallStatus: RECRUITING date: 2024-02-02 date: 2024-11 date: 2025-10 date: 2024-03-27 date: 2024-03-27 name: Autolus Limited class: INDUSTRY briefSummary: This is a Phase I study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE. conditions: Systemic Lupus Erythematosus studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Obecabtagene autoleucel (obe-cel) measure: Dose limiting toxicities measure: Adverse events measure: Remission rate according to Definition of Remission in SLE (DORIS) measure: Response over time according to Definition of Remission in SLE (DORIS) measure: Time to response according to Definition of Remission in SLE (DORIS) measure: Change over time in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) measure: Change over time in Physician's global assessment (PGA) measure: Pharmacokinetics (maximum serum concentration [Cmax]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood measure: Pharmacokinetics (time to reaching maximum serum concentration [Tmax]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood measure: Pharmacokinetics (area under the curve [AUC]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood measure: Pharmacokinetics (last observed quantifiable concentration [Clast]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood measure: Pharmacokinetics (time to reach last observed quantifiable concentration [Tlast]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood measure: Pharmacodynamics: B cell aplasia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University College London Hospitals NHS Foundation Trust status: RECRUITING city: London country: United Kingdom name: Maria Leandro role: CONTACT email: uclh.car-ttrials@nhs.net lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06333470 id: 2024KYPJ025 briefTitle: Liwan Eye Study: the Fourth Follow-up overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-09-30 date: 2024-09-30 date: 2024-03-27 date: 2024-03-28 name: Zhongshan Ophthalmic Center, Sun Yat-sen University class: OTHER briefSummary: Primary angle-closure glaucoma (PACG) is one of the major causes of blindness affecting more than 20 million patients worldwide. The goals of this observational cohort study are to investigate the 20-year incidence of PACG in Chinese population aged 50 years and to develop prediction models for the long-term risk of progression from primary angle-closure suspect (PACS) to PACG. conditions: Primary Angle-Closure Glaucoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 600 type: ESTIMATED name: Primary angle closure diseases measure: The 20-year incidence of primary angle-closure glaucoma (PACG) in Chinese population aged over 50 years measure: The development of prediction models for the long-term risk of progression from primary angle-closure suspect (PACS) to primary angle-closure glaucoma (PACG) measure: The 20-year incidence of visual impairment in Chinese population aged over 50 years sex: ALL minimumAge: 70 Years maximumAge: 100 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333457 id: EA4/024/24 briefTitle: Presence and Relapse Rates in Patients With Alcohol Use Disorder Using Virtual Reality acronym: PRE-VR overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-11-01 date: 2025-02-01 date: 2024-03-27 date: 2024-03-27 name: Charite University, Berlin, Germany class: OTHER briefSummary: Investigation of the influence of the sense of presence during a Virtual Reality Cue-Exposure Therapy (VR-CET) with alcohol-associated cues on craving and relapse rates.
Primary hypothesis: the experience of presence during a virtual presentation of alcohol in alcohol-dependent patients is associated with levels of craving for alcohol during VR-CET. conditions: Alcohol Dependence studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: VR Cue-Exposure Therapy measure: Craving measure: Craving measure: Craving measure: Relapse rates measure: Quality of Life measure: Motion Sickness measure: Presence in VR sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Psychiatric University Hospital Charité at St. Hedwig Hospital city: Berlin zip: 10115 country: Germany lat: 52.52437 lon: 13.41053 hasResults: False
nctId: NCT06333444 id: n. 08, 09/03/2021 briefTitle: Counselling Intervention for College Students Experienced Psychological Distress acronym: TRESPASS overallStatus: RECRUITING date: 2022-01-01 date: 2024-12-31 date: 2025-12-31 date: 2024-03-27 date: 2024-03-27 name: University of Campania "Luigi Vanvitelli" class: OTHER briefSummary: The goal of this clinical trial is to evaluate mental health and academic motivation in university students asking help to university counselling service (UCS) in Southern Italy before anf after four weekly psychological sessions.
* which psychological variables predict the intervention outcome conditions: University Students conditions: Psychological Intervention conditions: Psychological Distress studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Four weekly psychological counselling intervention primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: four weekly psychological counselling intervention measure: psychological distress measure: Academic motivation measure: Emotion regulation ability measure: perceived loneliness measure: drop-out intention sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: University of Campania status: RECRUITING city: Caserta zip: 81100 country: Italy name: ALDA TRONCONE role: CONTACT email: alda.troncone@unicampania.it lat: 41.07262 lon: 14.33231 hasResults: False
nctId: NCT06333431 id: WN/WF briefTitle: Effects of WN and WF During Gastroscopy acronym: WF/WN_GCPY overallStatus: NOT_YET_RECRUITING date: 2024-04-03 date: 2024-05-30 date: 2024-06-08 date: 2024-03-27 date: 2024-03-27 name: Suleyman Demirel University class: OTHER briefSummary: Background: Gastroscopy is an endoscopic procedure that allows examination of the upper gastrointestinal system, including the esophagus, stomach and duodenum. The procedure is a difficult and stressful diagnosis and treatment method for the patient. Problems such as stress, fear and pain experienced during endoscopy cause anxiety.
Purpose: To examine effects of glass waterfall and white noise on pain, anxiety and physiological parameters during gastroscopy Method: The population of the study consists of all patients who applied to Mardin Education and Research Hospital, Department of General Surgery, Endoscopy Unit and were scheduled for gastroscopy. The sample will be represented by 156 patients whose gastroscopy procedure is planned between the specified dates and who meet the criteria for inclusion in the sample. In calculating the sample of the study, power analysis was performed and it was found the effect size of 1.16, 95% power and 0.05% margin of error for this study, that a total of 156 individuals for the three groups and at 52 individuals for each group. Before gastroscopy procedure, the patients included in the study will be randomly divided into three groups: 52 glass waterfall group, 52 white noise group and 52 control group. conditions: Misadventure During Endoscopic Examination studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment experimental model using randomized pretest and posttest with control group primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 156 type: ESTIMATED name: Glass Waterfall group name: white noise group measure: Patient Information Form measure: Visual Analogue Scale (VAS) measure: State and Trait Anxiety Scale (STAI) measure: The Patient Observation Form measure: Pulse rate before and after gatroscopy procedure measure: Respiratory rate before and after gatroscopy procedure measure: Systolic and diastolic blood pressure before and after gatroscopy procedure measure: Oxygen saturation values before and after gatroscopy procedure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333418 id: VR/WF briefTitle: Effects of VR and Glass WF Colonoscopy acronym: VR/WN_colon overallStatus: NOT_YET_RECRUITING date: 2024-04-03 date: 2024-05-30 date: 2024-06-08 date: 2024-03-27 date: 2024-03-27 name: Suleyman Demirel University class: OTHER briefSummary: Background: Today, colonoscopy is widely used in many diseases, especially in the screening and diagnosis of colorectal cancers. Colonoscopy is considered a procedure that disturbs the patient's comfort because it is a very invasive and painful procedure. Along with physical discomfort during the procedure, it triggers emotional disturbances such as fear, and anxiety in the patient.
Purpose: To examine the effect of virtual rain forest and glass waterfall on satisfaction, comfort, anxiety, and vital signs before colonoscopy Method: The population of the study consists of all patients who applied to Mardin Education and Research Hospital, Department of General Surgery, Endoscopy Unit and were scheduled for colonoscopy. The sample will be represented by 135 patients whose colonoscopy procedure is planned between the specified dates and who meet the criteria for inclusion in the sample. In calculating the sample of the study, power analysis was performed and it was found the effect size of 0.40, 95% power and 0.01% margin of error for this study, that a total of 135 individuals for the three groups and at 60 individuals for each group. G\*Power, version 3.0.10 was used for statistical power analysis. The study group of 93 people to participate in the study will be divided into three equal groups in accordance with the random numbers table obtained the computer- based Research Randomizer program. Before the arthroscopy procedure, the patients included in the study will be randomly divided into three groups: 45 rain forest video VR group, 45 glass waterfall group and 45 control group. All participants in the study will first fill out a patient identification form containing patient demographic information. conditions: Misadventure During Endoscopic Examination studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment experimental model using randomized pretest and posttest with control group primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Double (Participant, Investigator) whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 135 type: ESTIMATED name: Virtual Reality Glasses Group name: Glass waterfall measure: Patient Information Form measure: Visual Analogue Scale (VAS) measure: State and Trait Anxiety Scale (STAI) measure: The Patient Observation Form measure: Pulse rate before colonoscopy procedure measure: Respiratory rate before colonoscopy procedure measure: Systolic and diastolic blood pressure before colonoscopy procedure measure: Oxygen saturation values before colonoscopy procedure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333405 id: FMTNEC/01/2024 briefTitle: Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) - Clinical Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-01-31 date: 2025-01-31 date: 2024-03-27 date: 2024-03-27 name: Medical University of Warsaw class: OTHER briefSummary: The aim of the study is to assess the safety of fecal microbiota transplantation (FMT) as a preventive method for the development of Necrotizing enterocolitis (NEC) in a group of premature infants.
This is the first stage of a clinical trial testing the effectiveness of FMT in NEC, the aim of which is to examine the safety profile and analyze all side effects. conditions: Necrotizing Enterocolitis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: single group, open label, observational study with intervention (FMT) primaryPurpose: PREVENTION masking: NONE count: 20 type: ESTIMATED name: Fecal Microbiota Transplantation measure: Adverse reactions monitoring sex: ALL minimumAge: 24 Weeks maximumAge: 36 Weeks stdAges: CHILD facility: Medical University of Warsaw, Pediatric Surgery Clinic city: Warsaw state: Mazovian Voivodeship zip: 02-097 country: Poland name: Marek Wolski, MD, PhD role: CONTACT phone: 665578922 phoneExt: +48 email: marek.wolski@wum.edu.pl name: Ewa A. Biegańska, MD role: CONTACT phone: 692542543 phoneExt: +48 email: ewa.bieganska@wum.edu.pl lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06333392 id: TotalUnderwater_REK577567 briefTitle: Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-12 date: 2024-03-27 date: 2024-03-27 name: Vestre Viken Hospital Trust class: OTHER name: Ullevaal University Hospital name: Sahlgrenska University Hospital, Sweden name: Ostfold Hospital Trust briefSummary: Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening, in screening programmes often as a work-up examination after a positive primary screening test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs are typically located in the right colon. They are flat, with indistinctive boarders, and consequently easily missed or incompletely resected. A Norwegian study showed incomplete resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men, with women being on a threefold risk of developing CRC from SSLs. It seems like post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water infusion to distend the lumen and visualise the mucosa during withdrawal of the colonoscope and simultaneously removal of water. There are several reasons to advocate TUC:
* Good health and well-being: The increased detection and improved complete removal of sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality during follow-up. TUC will probably reduce the rate of painful procedures and vasovagal reactions and thus increase the acceptance of a screening programme. Consequently, the project can contribute significantly to improve screening effectiveness in Norway and Sweden, particularly in women (women have a higher risk for SSLs and a higher risk of colorectal cancer developing from this type of precursor).
* Gender equality: Women have a similar lifetime risk for CRC as men but less benefit of screening regardless of whether they are screened by sigmoidoscopy, FIT or colonoscopy. The reason is probably missed sessile serrated lesions in the proximal colon. If TUC improves SSLDR and complete lesion resection, this may lead to an equal benefit from CRC screening for women and men. Women have also a higher risk of discomfort and pain during colonoscopy than men. It has been shown that women prefer non-invasive screening modalities, potentially to avoid pain during colonoscopy, even if colonoscopy may be the most beneficial screening method for women. If TUC reduces the rate of painful colonoscopies, it can reduce women's barriers to attend screening.
* Responsible consumption and production: The TUC technique will also reduce the ecological footprint of colonoscopy activity due to reduced consumption of single use accessories and reduced number of colonoscopies to achieve polyp free colon. Furthermore, the cost for the health care system will be substantially reduced. conditions: Colorectal Neoplasia conditions: Screening Colonoscopy conditions: Colorectal Cancer conditions: Colorectal Cancer Screening conditions: Vasovagal Reaction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 1070 type: ESTIMATED name: Total underwater colonoscopy name: Conventional colonoscopy measure: Proximal sessile serrated lesion detection rate measure: Complete resection rate for lesions > 10mm measure: Rate of painful procedures and vasovagal reactions measure: Leakage after colonoscopy measure: Detection rate for other neoplasia than SSL measure: Withdrawal time measure: Total procedure time measure: Bowel cleansing quality measure: Complications measure: Number of colonoscopies to achieve polyp free colon measure: Single use accessories for the procedure sex: ALL minimumAge: 55 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06333379 id: SichuanPPHLC04 id: 2020LY01 type: OTHER_GRANT domain: Sichuan Provincial People's Hospital briefTitle: Aspergillosis Detection Via EBC-GM in Ventilated Patients overallStatus: COMPLETED date: 2023-01-02 date: 2023-12-30 date: 2024-01-10 date: 2024-03-27 date: 2024-03-27 name: Lin Chen class: OTHER briefSummary: Brief Research Proposal: Non-Invasive Detection of Invasive Pulmonary Aspergillosis in ICU Patients Background: Invasive Pulmonary Aspergillosis (IPA) is a critical threat to patients in ICUs, especially those undergoing mechanical ventilation. Traditional diagnostic methods are invasive and carry risks. This study proposes a non-invasive, innovative approach utilizing galactomannan (GM) analysis in Exhaled Breath Condensate (EBC) for early IPA detection.